Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Pisapia DJ, Rosenblum MK, Lavi E. CD1a Reactivity in Non-neoplastic Adenohypophysis. Am J Surg Pathol. 2016;40(6):812-7.

Cushing MM, Asmis L, Calabia C, Rand JH, Haas T. Efficacy of solvent/detergent plasma after storage at 2-8 °C for 5 days in comparison to other plasma products to improve factor V levels in factor V deficient plasma. Transfus Apher Sci. 2016;55(1):114-9.

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 2016;48(12):1490-1499.

Patel AD, Schneider Y, Saumoy M, Maltz C, Yeo H, Jessurun J, et al. Idiopathic Myointimal Hyperplasia of the Mesenteric Veins. ACG Case Rep J. 2016;3(4):e84.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, et al. Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2016;156(2):405-6.

Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, et al. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr. 2016;103(3):851-60.

Santo EE, Paik J. FOXO3a & haematopoietic stem cells: Goodbye PI3K, hello SIRT1? Cell Cycle. 2016;15(7):879-80.

Evans JR, Zhao SG, S Chang L, Tomlins SA, Erho N, Sboner A, et al. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncol. 2016;2(4):471-80.

Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559-63.

Cohen T, Schwarz TM, Vigant F, Gardner TJ, Hernandez RE, Lee B, et al. The Microtubule Inhibitor Podofilox Inhibits an Early Entry Step of Human Cytomegalovirus. Viruses. 2016;8(10).